Delivering tomorrow’s
genetic medicines,
today™
With the emergence of gene therapies, we are at a crucial turning point in human history.
“LNP-RNA drugs are rapidly causing a revolution in medicine. Almost any disease you care to name can potentially be treated using an RNA-based gene therapy” — Co-Founder Dr. Pieter Cullis
At NanoVation TherapeuticsTM, we are making this future a reality by enabling the safe and efficient delivery of genetic medicines to target tissues in the body.
NanoVation is delivering tomorrow’s genetic medicines today.
OUR VISION:
OUR MISSION:
Our next-generation platform technologies use lipid nanoparticles to deliver nucleic acids to a variety of tissues
NanoVation TherapeuticsTM develops scalable, nucleic acid-agnostic lipid nanoparticle (LNP) formulations customized for specific targets, payloads and routes of administration.
We’re delivering tomorrow’s genetic medicines, today.
NanoVation Therapeutics™ provides a leading one-stop-shop IP portfolio to empower your genetic medicines
mRNA modifications
Specialty (ionizable) lipids
Surface modifications
LNP compositions
Our multidisciplinary team includes world-leading experts in lipid chemistry, RNA design and nucleic acid delivery
Our world-leading team has the know-how for end-to-end collaboration in the drug development process, empowering partners to rapidly develop their genetic medicines.
NanoVation Therapeutics™ is headquartered in Vancouver, BC, Canada
European Office
Berlin, Germany
Our toolbox
Unique ionizable lipid libraries
NanoVation TherapeuticsTM uses bucket chemistry to create extensive lipid libraries at a low cost, with easier synthesis, at a higher yield, and with a higher therapeutic index.
High-yield✓
Biodegradable✓
Improved potency✓
LNP compositions
- Rationally designed lipid nanoparticles (LNPs) for a variety of tissues including: delivery to bone marrow, immune compartments, and solid tumors.
- Nucleic agnostic: Encapsulating a variety of payloads (siRNA, mRNA, DNA, etc.).
- Rigorously characterized for nucleic acid and lipid content, entrapment, particle size and polydispersity.
The long-circulating LNP (lcLNP™)
NanoVation’s flagship technology – the long-circulating LNP (lcLNP™) – enables the functional delivery of nucleic acids to extrahepatic tissues including bone marrow, tumors, and skin.
- Extended systemic circulation for efficient extrahepatic delivery.
- Improved safety profile.
- Enhanced efficacy in extrahepatic tissues.
Surface modifications
NanoVation TherapeuticsTM expands the range of surface modifications to improve tolerability and increase target specificity. This includes PEGless LNP compositions as well as opportunities to modify our lcLNP technology with targeting ligands.
mRNA modifications
- In-house in vitro mRNA synthesis from DNA templates with optimized translational efficiency and stability
- Different mRNA constructs available for a variety of biological applications.
- In vitro transcribed mRNA characterized for purity, capping efficiency and endotoxin levels.
- Novel proprietary RNA caps that greatly increase the efficiency of mRNA translation.